154 related articles for article (PubMed ID: 22983062)
1. Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI.
Sirajuddin P; Das S; Ringer L; Rodriguez OC; Sivakumar A; Lee YC; Üren A; Fricke ST; Rood B; Ozcan A; Wang SS; Karam S; Yenugonda V; Salinas P; Petricoin E; Pishvaian M; Lisanti MP; Wang Y; Schlegel R; Moasser B; Albanese C
Cell Cycle; 2012 Oct; 11(20):3801-9. PubMed ID: 22983062
[TBL] [Abstract][Full Text] [Related]
2. VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells.
Ringer L; Sirajuddin P; Heckler M; Ghosh A; Suprynowicz F; Yenugonda VM; Brown ML; Toretsky JA; Uren A; Lee Y; MacDonald TJ; Rodriguez O; Glazer RI; Schlegel R; Albanese C
Cancer Biol Ther; 2011 Nov; 12(9):818-26. PubMed ID: 21885916
[TBL] [Abstract][Full Text] [Related]
3. VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells.
Ringer L; Sirajuddin P; Yenugonda VM; Ghosh A; Divito K; Trabosh V; Patel Y; Brophy A; Grindrod S; Lisanti MP; Rosenthal D; Brown ML; Avantaggiati ML; Rodriguez O; Albanese C
Cancer Biol Ther; 2010 Aug; 10(4):320-5. PubMed ID: 20574155
[TBL] [Abstract][Full Text] [Related]
4. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
Yenugonda VM; Deb TB; Grindrod SC; Dakshanamurthy S; Yang Y; Paige M; Brown ML
Bioorg Med Chem; 2011 Apr; 19(8):2714-25. PubMed ID: 21440449
[TBL] [Abstract][Full Text] [Related]
5. The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells.
Ringer L; Sirajuddin P; Tricoli L; Waye S; Choudhry MU; Parasido E; Sivakumar A; Heckler M; Naeem A; Abdelgawad I; Liu X; Feldman AS; Lee RJ; Wu CL; Yenugonda V; Kallakury B; Dritschilo A; Lynch J; Schlegel R; Rodriguez O; Pestell RG; Avantaggiati ML; Albanese C
Oncotarget; 2014 Nov; 5(21):10678-91. PubMed ID: 25296977
[TBL] [Abstract][Full Text] [Related]
6. The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells.
Waye S; Naeem A; Choudhry MU; Parasido E; Tricoli L; Sivakumar A; Mikhaiel JP; Yenugonda V; Rodriguez OC; Karam SD; Rood BR; Avantaggiati ML; Albanese C
Aging (Albany NY); 2015 Oct; 7(10):854-68. PubMed ID: 26540407
[TBL] [Abstract][Full Text] [Related]
7. The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma.
Kumar A; Fillmore HL; Kadian R; Broaddus WC; Tye GW; Van Meter TE
Mol Cancer Res; 2009 Nov; 7(11):1813-21. PubMed ID: 19887560
[TBL] [Abstract][Full Text] [Related]
8. New therapies for prostate cancer?
Tanowitz HB; Machado FS
Cancer Biol Ther; 2010 Aug; 10(4):326-8. PubMed ID: 20703097
[No Abstract] [Full Text] [Related]
9. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.
Yang F; Jove V; Chang S; Hedvat M; Liu L; Buettner R; Tian Y; Scuto A; Wen W; Yip ML; Van Meter T; Yen Y; Jove R
Cancer Biol Ther; 2012 Apr; 13(6):349-57. PubMed ID: 22313636
[TBL] [Abstract][Full Text] [Related]
11. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.
Knockaert M; Lenormand P; Gray N; Schultz P; Pouysségur J; Meijer L
Oncogene; 2002 Sep; 21(42):6413-24. PubMed ID: 12226745
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
13. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
[TBL] [Abstract][Full Text] [Related]
14. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.
Siemeister G; Lücking U; Wengner AM; Lienau P; Steinke W; Schatz C; Mumberg D; Ziegelbauer K
Mol Cancer Ther; 2012 Oct; 11(10):2265-73. PubMed ID: 22821149
[TBL] [Abstract][Full Text] [Related]
15. CNS Penetration of Cyclophosphamide and Metabolites in Mice Bearing Group 3 Medulloblastoma and Non-Tumor Bearing Mice.
Campagne O; Davis A; Zhong B; Nair S; Haberman V; T Patel Y; Janke L; F Roussel M; Stewart C
J Pharm Pharm Sci; 2019; 22(1):612-629. PubMed ID: 31815662
[TBL] [Abstract][Full Text] [Related]
16. MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma.
Filocamo G; Brunetti M; Colaceci F; Sasso R; Tanori M; Pasquali E; Alfonsi R; Mancuso M; Saran A; Lahm A; Di Marcotullio L; Steinkühler C; Pazzaglia S
Mol Cancer Ther; 2016 Jun; 15(6):1177-89. PubMed ID: 26960983
[TBL] [Abstract][Full Text] [Related]
17. Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma.
Pambid MR; Berns R; Adomat HH; Hu K; Triscott J; Maurer N; Zisman N; Ramaswamy V; Hawkins CE; Taylor MD; Dunham C; Guns E; Dunn SE
Pediatr Blood Cancer; 2014 Jan; 61(1):107-15. PubMed ID: 23940083
[TBL] [Abstract][Full Text] [Related]
18. The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma.
Andrade AF; Borges KS; Suazo VK; Geron L; Corrêa CA; Castro-Gamero AM; de Vasconcelos EJ; de Oliveira RS; Neder L; Yunes JA; Dos Santos Aguiar S; Scrideli CA; Tone LG
Invest New Drugs; 2017 Feb; 35(1):26-36. PubMed ID: 27785591
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a sensitive LC MS/MS method for the measurement of the checkpoint kinase 1 inhibitor prexasertib and its application in a cerebral microdialysis study.
Zhong B; Maharaj A; Davis A; Roussel MF; Stewart CF
J Pharm Biomed Anal; 2018 Jul; 156():97-103. PubMed ID: 29698863
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Long Noncoding RNA CRNDE Increases Chemosensitivity of Medulloblastoma Cells by Targeting miR-29c-3p.
Sun XH; Fan WJ; An ZJ; Sun Y
Oncol Res; 2020 Feb; 28(1):95-102. PubMed ID: 31753063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
